[Degradation kinetics of β-nicotinamide mononucleotide based on reliable HPLC quantitative method].
Level 5 - mechanism / opinion, no new human data
In vitro analytical method development and bench degradation kinetics study with no human subjects.
PubMed 38212023 · doi:10.19540/j.cnki.cjcmm.20230905.301
What was done
The authors established a reversed-phase HPLC method (Welch Xtimate AQ-C18 column, 266 nm detection, methanol and 10 mmol/L ammonium formate gradient) to quantify β-nicotinamide mononucleotide (NMN) in a simple substrate. They evaluated method parameters (linearity, precision, recovery) and investigated the degradation kinetics and behavior of NMN across varying temperatures, pH conditions, and enzymatic exposures (pepsin and trypsin).
What was found
The HPLC assay showed high linearity (R² ≥ 0.9999), instrument precision RSD of 0.26%, and an average recovery of 98.71% (RSD = 1.2%). NMN in aqueous solution degraded according to apparent first-order kinetics, primarily driven by elevated temperature and extreme pH (strong acid or strong alkali). Pepsin and trypsin had minimal impact on degradation rate. In aqueous solution at room temperature, degradation followed lg C_t = 0.005 7t + 4.817 2, yielding a t_0.9 (time to 10% degradation) of 95.58 hours and a half-life (t_1/2) of 860.26 hours.
Why it matters
These quantitative stability benchmarks define the temperature and pH boundaries required for processing, formulating, and storing aqueous NMN products to prevent premature degradation.
Limits
The study was conducted entirely in vitro using simple aqueous substrates and isolated enzymes, without assessing stability in complex biological matrices, digestive fluids, or clinical formulations. In vivo pharmacokinetics, bioavailability, and physiological stability were not evaluated.
Cited by
- contradicts Commercial NMN supplement products break down and become inert within 30 to 45 days.